Skip to content
Companies

Curadel Surgical Innovations

Fluorescent drug that makes ureters visible in surgery

Raised to date

$49.8M

of $57.5M offered across 1 Form D filing

Still open
$7.7M
Investors
39
Last filed
Oct 13, 2026

About

Curadel Surgical Innovations develops near-infrared fluorescent contrast agents for image-guided surgery based on the FLARE technology, licensed from Beth Israel Deaconess Medical Center. Its lead agent, ZW800-1 (nizaracianine triflutate), is given intravenously so surgeons can see the ureters and avoid injuring them during abdominopelvic surgery, and is in a recruiting Phase 2/3 trial. The company is developing further agents to highlight tumors, blood vessels, nerves, lymph nodes and cartilage.

Zwitterionic near-infrared fluorophores from the FLARE platform, which can image two NIR channels at once in real time.

Funding

$57.5M round, Sep 2026$49.8M sold$7.7M still openJun 2026Aug
Now
  • EquityFiled Oct 13, 2026Form D
    $49.8M/ $57.5M

Product

ZW800-1 (nizaracianine triflutate)

Surgical contrast agent

Investigational intravenous near-infrared fluorescent agent that makes the ureters visible under fluorescence imaging during abdominopelvic surgery.

  • Near-infrared fluorescence visible with surgical imaging systems
  • Up to three IV bolus doses during surgery
  • Shows ureter location and function

Built for

Hospitals and surgeons performing abdominopelvic and oncologic surgery

People on file